StemCell Therapy

Aravive Inc (ARAV) is near the top in its industry group according to InvestorsObserver. ARAV gets an overall rating of 81. That means it scores higher than 81 percent of stocks. Aravive Inc gets a 98 rank in the Biotechnology industry. Biotechnology is number 87 out of 148 industries.

Click Here to get the full Stock Score Report on Aravive Inc (ARAV) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 81 means the stock is more attractive than 81 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Aravive Inc (ARAV) stock has fallen -15.53% while the S&P 500 has gained 0.17% as of 10:44 AM on Wednesday, Nov 27. ARAV is lower by -$1.46 from the previous closing price of $9.40 on volume of 1,348,672 shares. Over the past year the S&P 500 has risen 17.28% while ARAV has gained 43.06%. ARAV lost -$6.00 per share the over the last 12 months.

To screen for more stocks like ARAV click here.

View post:
Where Does ARAV Stock Rank in the Biotechnology Industry? - InvestorsObserver

This entry was posted on November 28, 2019 at 4:46 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |